Information for Authors - - BioPharm International

ADVERTISEMENT

Information for Authors

BioPharm International

BioPharm International integrates the science and business of biopharmaceutical development, and manufacturing. We provide practical, peer-reviewed technical articles to enable biopharmaceutical professionals to perform their jobs more effectively. We believe that technical decisions are also business decisions and give readers the tools to make both sound business and technical decisions.

More than 30,200 readers worldwide count on BioPharm International for emerging tools and trends for formulating, developing, delivering, and manufacturing pharmaceutical products through biotechnology. Readers are involved in product and process development, manufacturing, quality control/quality assurance, analytical technologies, regulatory affairs, plant and project engineering and design, and corporate management for the entire scope of biopharmaceutical products, including therapeutic peptides, proteins, nucleic acids, and cells for cell therapies and regenerative medicine, as well as both therapeutic and prophylactic vaccines.

BioPharm International articles help keep our readers up-to-date on technical and regulatory topics including:
• upstream processing (protein expression, fermentation & cell culture) and process development
• downstream processing (separation and purification) and process development;
• drug formulation and delivery;
• validation;
• GMP compliance and quality control;
• analytical technologies;
• scale-up strategies; and
• facilities design and expansion.

We also cover business topics such as:
• supply-chain management;
• sourcing and outsourcing;
• project management;
• partnerships; and
• intellectual property management.

BioPharm International’s readers are also its authors. You can help us meet your needs by submitting manuscripts that offer technical and scientific discussions of ongoing drug development challenges and solutions.

Submitted manuscripts should be sufficiently novel to be of interest to an experienced audience. Articles should be data driven and provide sufficient technical detail to support the main thesis or should offer a novel synthesis of existing data. Topics should be timely and useful and should focus on the development of peptides, monoclonal antibodies, fusion proteins, other therapeutic proteins, nucleic acids, vaccines, cells for cell therapy, and any other class of biotechnologically generated molecular class.

Peer-review Articles
Articles submitted for peer review may fall into four main categories: standard data-driven, novel research paper; topical literature or patent review; technical case studies/technical application notes; and science-based opinion papers. See the author guidelines for peer-review papers for details.

BioPharm International will consider original technical and scientific review articles that have never been previously published in any format, print or electronic, and are not under consideration at any other journal during the period they’re under review at BioPharm International.

To contribute, view BioPharm International's Author Guidelines for Peer-Review Papers - 2014 or Author Guidelines for Supplements and Technical Articles [downloadable PDFs].

View the 2014 Editorial Calendar.

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines
Source: BioPharm International,
Click here